NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization41.24 mln
Float0.53 mln
Earnings Date08/14/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
23
/ 100
Significantly lagging
Debt / Equity
-0.08
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Eloxx Pharmaceuticals is a clinical-stage drug development company headquartered in Arlington, Massachusetts, with operations in Israel and Australia. The company focuses on treatments for rare genetic diseases caused by nonsense mutations ? errors in genetic code that cause the body to stop producing essential proteins too early. Its lead drug candidate, ezutromid, is being tested in clinical trials for rare kidney conditions, while a separate compound is being developed with partner Almirall S.A. to treat serious inherited skin disorders.